linjc16/ctgov huggingface dataset:
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages

Study Overview
=================
Brief Summary
-----------------
The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.

Detailed Description
-----------------
The study is planned as open, randomised 3-period cross-over in patients with T1DM. The study will include a total of 6 completing patients. The study is not blinded due to the exploratory nature. At each of the 3 periods, different blood glucose level will be established in 4 steps (8, 6, 4, and 2.8 mmol/L), and a prefixed glucagon dose will be given per glucose level. The sequence of glucagon dose strength for the three dosing days will be randomized.

Official Title
-----------------
A Randomised, Single Center, Three-period Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages at Four Different Blood Glucose Concentrations

Conditions
-----------------
Diabetes Mellitus Type 1

Intervention / Treatment
-----------------
* Drug: Glucagon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subjects with diabetes mellitus type 1 , as defined by the American Diabetes Association1. Age ≥ 18 and ≤ 65 years. Exclusion Criteria: Known or suspected hypersensitivity to trial product(s) or related products. Receipt of any investigational medicinal product within 3 months or 5 half-lives of that IMP before randomisation in this trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Glucagon level: 0,11 and 1 mg<br>Glucagon level: 0,11 and 1 mg | Drug: Glucagon<br> <br> |
| Experimental: Glucagon level: 0,22 and 0,66 mg<br>Glucagon level: 0,22 and 0,66 mg | Drug: Glucagon<br> <br> |
| Experimental: Glucagon level: 0,44 and 0,33 mg<br>Glucagon level: 0,44 and 0,33 mg | Drug: Glucagon<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCGlucose of different glucagon dosages given s.c. |  | 90 min after dosing |
Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting

Study Overview
=================
Brief Summary
-----------------
Gastric emptying is delayed after cardiac surgery, but the efficacy of the nasogastric (NG) tube in preventing distension and reducing vomiting is unclear. Nasogastric (NG) tubes are routinely used in patients undergoing surgery. They are presumed to reduce postoperative nausea and vomiting (PONV) and to lessen the risk of aspiration by reducing residual gastric volumes; however, their insertion and use is not however without potentially serious complications. Existing literature does not address their efficacy in reducing PONV after cardiac surgery. However, current evidence suggests that up to 50% of patients in this group suffer significant nausea and vomiting. The objective of this study is to determine whether NG tubes should continue to be inserted routinely during cardiac surgery to reduce PONV.

Official Title
-----------------
Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting. A Prospective Randomized Clinical Trial.

Conditions
-----------------
Heart Disease

Intervention / Treatment
-----------------
* Device: Placement of nasogastric tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergoing coronary artery bypass graft and/or valvular surgery, age 18-80 year olds signed informed consent elective or urgent surgery Exclusion Criteria: past history of oesophageal surgery, oesophageal varices or stricture, patients who have received antiemetic medication in the 24 hours before surgery emergency surgery patients that require re-sternotomy, or are not extubated 24 hours after admission to the intensive care unit, will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Placement of nasogastric tube|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary outcome measures will be the incidence and severity of postoperative nausea and vomiting as well as paint while the patient is in the CVICU |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasogastric Tubes, Nausea, Vomiting, Cardiac surgery
Assessment of Coronary Flow Reserve by PET-H215O and FFR. Comparison With Dynamic Acquisition Using CZT Camera

Study Overview
=================
Brief Summary
-----------------
The study will assess coronary flow reserve by PET-H215O and FFR in patients suspected of coroanry artery disease. This a comparative study with dynamic acquisition using CZT camera and 99mcTc-mibi. 20 patients will have those measurements.

Official Title
-----------------
Assessment of Coronary Flow Reserve by PET-H215O and FFR in Patients Suspected of Coroanry Artery Disease. a Comparative Study With Dynamic Acquisition Using CZT Camera and 99mcTc-mibi.

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient between 18 and 80 years Suspected coronary disease and / or coronary syndrome patient ST- Patient who has been informed of the study and has given his informed consent Patient affiliated to a social security system. Exclusion Criteria: Patient having no coronary disease at coronary angiography with FFR on the 3 main epicardial arteries (absence of ≥ 50% stenosis of at least one artery) Delay of Care grater than 30 days between the PET and SPECT imaging and the diagnostic coronary angiography Patient with a recent history of myocardial infarction and STEMI, unstable angina Patient with extra-cardiac disease whose prognosis can interfere with the treatment decision Pregnant or lactating women Patient allergic to contrast products during coronary angiography Patient with MDRD clearance les than 60 ml / min Patient Under guardianship, or unable to understand the purpose of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR<br> | Other: ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess myocardial coronary reserve by cardiac CZT camera and Tcmibi comparing with the PET and the water marked during coronary FFR (Flow Fraction Reserve) |  | baseline |
The Impact of Preoperative Fasting Period on Cardiac Index Variability After Anesthesia Induction in Pediatric Patients

Study Overview
=================
Brief Summary
-----------------
The minimum period of fasting recommended by the 'American Society of Anesthesiologists' for the preoperative period is 6 hours for solid foods and 2 hours for clear liquids. Knowing the effect of preoperative fasting time on intravascular volume status may lead us to determine the amount of fluid to be administered intraoperatively. Cardiac preload static indicators are often insufficient to predict the need for fluid and are often measured by invasive methods. Knowing the adequacy of the preload is important in anesthesia practice; there is no hemodynamic benefit of fluid replacement in non-responsive patients. In this study, the investigators aimed to determine the effect of preoperative fasting period on cardiac index change after anesthesia induction in pediatric patients aged 5-12 years. The primary implication of this study is to determine the fasting period of fluid evacuation by assessing patients' intravascular volume status.

Official Title
-----------------
The Impact of Preoperative Fasting Period on Cardiac Index Variability After Anesthesia Induction in Pediatric Patients

Conditions
-----------------
Fasting Period, Intravascular Volume

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients, aged between 5 to 12, undergoing surgery - Exclusion Criteria: any comorbidity -

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the relationship between fasting period duration and fluid responsiveness |  | March 2018 |
Development and Validation of the Food Acceptability Questionnaire

Study Overview
=================
Brief Summary
-----------------
The Food Acceptability Questionnaire (FAQ) is a self-report measure of palatability, ease of preparation, satisfaction, and perceived benefits and adverse effects related to a prescribed or self-selected diet. This study intends to develop a reliable and valid food acceptability questionnaire for use in clinical studies in which dietary interventions are administered.

Detailed Description
-----------------
Two hundred adult participants who follow a therapeutic diet will be recruited from the Washington DC area. Participants will be asked to rate their impression on the foods that they were eating in the past two weeks. Fifty participants will be chosen at random and asked to complete the questionnaire a second time, three weeks later, to assess reliability. Ratings will be used to assess the validity and reliability of the Food Acceptability Questionnaire (FAQ).

Official Title
-----------------
Development and Validation of the Food Acceptability Questionnaire

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must be older than 18 years and follow any kind of therapeutic diet. Exclusion Criteria: Those who have difficulty eating by themselves will be excluded. No vulnerable subjects will be included.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diet, acceptability, palatability, food, questionnaire, Food habits
Intrapulmonary Percussive Ventilation for Children With Bronchiolitis on Non-Invasive Ventilation Support

Study Overview
=================
Brief Summary
-----------------
Prospective randomized study of patients admitted to the Pediatric Intensive Care Unit suffering from Bronchiolitis and are supported on Non Invasive Positive Pressure Ventilation. The patient population will be divided into two groups, one group will receive conventional treatment and the other group will receive conventional treatment and three times a day of physiotherapy using Intrapulmonary Percussive Ventilation.

Official Title
-----------------
Prospective Randomized Controlled Study of the Use of Intrapulmonary Percussive Ventilation (IPV) for Children With Bronchiolitis Admitted to the Pediatric Intensive Care Unit (PICU) and Are on Non-Invasive Ventilation Support

Conditions
-----------------
Bronchiolitis

Intervention / Treatment
-----------------
* Device: Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bronchiolitis PICU patients Non Invasive Pressure Support Ventilation Age < 24 months Exclusion Criteria: Age > 24 months Invasive Ventilation No parental consent

Ages Eligible for Study
-----------------
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: Intrapulmonary Percussive Ventilation<br>15 minutes of IPV physiotherapy | Device: Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)<br>* IPV physiotherapy 3 times a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of PICU Stay |  | 10 days | 
| Need for Invasive Ventilation Support |  | 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| S/F ratio | Pulse oximetry saturation/fraction of inspired oxygen | Baseline, 15, 30 and 150 minutes after intervention | 
| Prevention of lung atelectasis | Per chest x-ray | 10 days |
Reducing Hazardous Alcohol Use in Social Networks Using Targeted Intervention: 21 Rising

Study Overview
=================
Brief Summary
-----------------
The primary goal of this study is to determine whether change in alcohol use among college students can be transmitted through social network ties to other members in the network. Members of one college class at a northeastern university will be enrolled in a longitudinal study in which they will provide self-reported behavioral information and information about their social ties to others in their college class. A subset of heavy drinking participants will be asked to meet in person to complete an interview about their alcohol use - called a Brief Motivational Interview. There is evidence that this sort of interview can reduce harmful alcohol use. The investigators expect that following the Brief Motivational Interview others in their friendship clusters will show reduced harm associated with alcohol use as well.

Official Title
-----------------
Reducing Hazardous Alcohol Use in Social Networks Using Targeted Intervention: 21 Rising

Conditions
-----------------
Alcohol Drinking, Alcohol; Harmful Use

Intervention / Treatment
-----------------
* Behavioral: Brief Motivational Interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Must be a member of the class of 2021 or 2021.5 at the site university Exclusion Criteria: • None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Brief Motivational Interview<br>Single-session in person conversation focusing on risks associated with alcohol use. | Behavioral: Brief Motivational Interview<br>* Single (60 min) session discussion of alcohol use and associated experiences.<br>|
| No Intervention: Natural History Control<br>No contact. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alcohol use | Average number of drinks per week in the past 30 days | At each follow up, measure average drinks per week in the past 30 days | 
| Average number of alcohol consequences in the past 30 days | Count of alcohol consequences in the past 30 days | At each follow up, measure count of alcohol consequences in the past 30 days |
Artificial Intelligence-enable Electrocardiogram for Diagnosis and Outcome in Hyperthyroidism

Study Overview
=================
Brief Summary
-----------------
hyperthyroidism

Official Title
-----------------
Artificial Intelligence-enable Electrocardiogram for Diagnosis and Outcome in Hyperthyroidism

Conditions
-----------------
Hyperthyroidism

Intervention / Treatment
-----------------
* Other: AI-enabled ECG-based Screening Tool


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in outpatient department. Patients recieved at least 1 ECG examination. Patients without TSH test before ECG examination or patients with subclinical hyperthyroidism without anti-thyroid drug usage. Exclusion Criteria: The patients recieved ECG at the period of inactive AI-ECG system.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Patients randomized to intervention will have access to the screening tool | Other: AI-enabled ECG-based Screening Tool<br>* Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.<br>|
| No Intervention: Control<br>Patients randomized to control will continue routine practice. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New-onset hyperthyroidism | A TSH of <0.25 IU/L | Within 30 days | 
| New-onset anti-throid drug treatment | New anti-throid drug treatment for patients with subclinical hyperthyroidism | Within 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | All-cause mortality | Within 1 year. | 
| Cardiac event | Heart failure, arrhythmia, etc. | Within 1 year. |
Low Dose Interscalene and Infraclavicular Block for Humerus Surgery

Study Overview
=================
Brief Summary
-----------------
Combining interscalene block with infraclavicular block for humerus surgery provides a unique surgical anaesthesia and postoperative analgesia.

Detailed Description
-----------------
Interscalene block provides effective surgical anaesthesia for shoulder and proximal arm surgery. However, sometimes it can be inadequate for distal arm surgery. Combining infraclavicular block with interscalene block may provide a successful surgical anaesthesia for humerus surgery.

Official Title
-----------------
Low Dose Interscalene and Infraclavicular Block for Humerus Surgery

Conditions
-----------------
Humerus Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients accepting peripheral nerve block technique for humerus surgery Unilateral orthopedic humerus surgery 18 years of age or older Exclusion Criteria: Patients refused peripheral nerve block Non-cooperate patients Neuropathy of any etiology in the affected extremity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate of block | A complete sensory loss in distribution of the radial, median, ulnar, musculocutaneous and medial cutaneous nerves of the arm | 10 min.- 20 min. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technique duration |  | 5 min. | 
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |  | 24 hours | 
| Complication rate |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
interscalene, infraclavicular, humerus surgery